NanoViricides, Inc. (NYSE American: NNVC) has announced that its broad-spectrum antiviral candidate, NV-387, warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company highlighted the absence of approved vaccines or therapies specifically targeting this virus strain, underscoring the urgent need for effective interventions.
NV-387 employs a host-targeted antiviral mechanism and is formulated for oral administration, which could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, and this ongoing development could support near-term regional availability if NV-387 is found effective against Ebola.
According to the company, the broad-spectrum nature of NV-387, along with its novel mechanism of action, positions it as a promising candidate for addressing emerging viral threats. The press release, available at https://ibn.fm/aSF5Z, details the rationale behind this strategic focus.
NanoViricides is a clinical-stage company specializing in nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for a range of viral infections, including respiratory syncytial virus (RSV), COVID-19, influenza, mpox, and others. The company’s technology is based on the TheraCour nanomedicine platform, licensed from TheraCour Pharma, Inc.
The company’s business model involves licensing technology for specific viral applications. NV-CoV-2, the company’s drug candidate for COVID-19, utilizes NV-387 as its active pharmaceutical ingredient, while NV-CoV-2-R encapsulates remdesivir within polymeric micelles. NanoViricides believes that its remdesivir-encapsulating drug could be more easily approvable given remdesivir’s existing FDA approval.
Beyond Ebola and mpox, NanoViricides is developing drugs against numerous viral diseases, including herpes, influenza, HIV, hepatitis C, rabies, dengue, and others. The company holds exclusive licenses for several human viral diseases under its agreement with TheraCour. However, the company acknowledges the inherent risks in drug development, noting that there can be no assurance that any of its candidates will prove effective or safe in human clinical trials.
For more information about NanoViricides and its latest updates, visit the company’s newsroom at https://ibn.fm/NNVC.
